Profile data is unavailable for this security.
About the company
Actinium Pharmaceuticals, Inc. specializes in the development of targeted radiotherapies. The Company is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). The Company is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. ATNM-400 is the Company's novel non-PSMA targeting Ac-225 radiotherapy for prostate cancer. Iomab-ACT, its conditioning candidate, is being developed to improve patient access and outcomes for potentially curative cell and gene therapies. Its Iomab-B program is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which it is seeking a potential strategic partner for the United States.
- Revenue in USD (TTM)90.00k
- Net income in USD-34.60m
- Incorporated2013
- Employees37.00
- LocationActinium Pharmaceuticals Inc100 Park Ave., 23Rd FloorNEW YORK 10017United StatesUSA
- Phone+1 (646) 677-3870
- Fax+1 (845) 818-3588
- Websitehttps://www.actiniumpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tvardi Therapeutics Inc | 4.02m | -13.95m | 33.30m | 10.00 | -- | 1.19 | -- | 8.28 | -8.36 | -8.36 | 0.7709 | 2.97 | 0.0891 | -- | -- | 402,400.00 | -30.87 | -36.79 | -40.26 | -41.45 | 100.00 | -- | -346.55 | -155.60 | -- | -- | 0.00 | -- | -65.96 | -18.53 | 40.20 | -- | 125.35 | -- |
| Bioqual Inc | 46.54m | 453.25k | 33.72m | 108.00 | 74.39 | 0.9427 | 12.28 | 0.7246 | 0.5068 | 0.5068 | 52.03 | 39.99 | 0.7111 | -- | 3.19 | -- | 0.6926 | 4.12 | 0.7745 | 4.83 | 12.85 | 16.15 | 0.974 | 4.03 | -- | -- | 0.00 | 32.81 | -16.60 | 1.06 | -316.79 | -- | -36.99 | -6.51 |
| Anebulo Pharmaceuticals Inc | 0.00 | -8.44m | 33.74m | 2.00 | -- | 3.46 | -- | -- | -0.2354 | -0.2354 | 0.00 | 0.237 | 0.00 | -- | -- | 0.00 | -128.22 | -108.15 | -145.11 | -112.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.45 | -- | -- | -- |
| Axe Compute Inc | 728.20k | -84.01m | 33.98m | 23.00 | -- | -- | -- | 46.66 | -120.02 | -120.66 | 1.29 | -100.94 | 0.1369 | 1.34 | 2.97 | 31,660.87 | -1,579.84 | -85.09 | -- | -113.42 | 50.24 | 61.31 | -11,536.93 | -1,267.27 | 0.0134 | -0.1392 | -- | -- | -0.2384 | 2.84 | 9.63 | -- | -18.60 | -- |
| Cypherpunk Technologies Inc | 0.00 | -50.81m | 34.48m | 52.00 | -- | 9.36 | -- | -- | -1.23 | -1.23 | 0.00 | 0.065 | 0.00 | -- | -- | 0.00 | -132.94 | -79.03 | -196.76 | -93.29 | -- | -- | -- | -9,055.53 | -- | -- | 0.00 | -- | -- | -- | 16.74 | -- | -- | -- |
| Xilio Therapeutics Inc | 31.80m | -58.49m | 35.11m | 64.00 | -- | -- | -- | 1.10 | -0.6571 | -0.6571 | 0.3348 | -0.1562 | 0.3053 | -- | -- | 496,937.50 | -56.14 | -67.88 | -102.68 | -81.71 | -- | -- | -183.90 | -5,578.28 | -- | -2.84 | -- | -- | -- | -- | 23.77 | -- | -45.00 | -- |
| Protext Mobility Inc | 750.00 | -2.21m | 35.16m | 4.00 | -- | -- | -- | 46,886.52 | -0.4692 | -0.4692 | 0.00001 | -0.0102 | 0.0405 | -- | -- | -- | -9,400.97 | -1,587.94 | -- | -- | 86.67 | -530.19 | -232,392.00 | -17,498.83 | 0.0002 | -1.36 | -- | -- | -93.98 | -63.09 | 27.35 | -- | -- | -- |
| Jasper Therapeutics Inc | 0.00 | -91.02m | 35.54m | 64.00 | -- | 3.07 | -- | -- | -5.90 | -5.90 | 0.00 | 0.4135 | 0.00 | -- | -- | 0.00 | -116.04 | -75.11 | -147.54 | -86.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -10.55 | -- | -- | -- |
| Veru Inc | 0.00 | -15.68m | 35.95m | 20.00 | -- | 1.79 | -- | -- | -1.07 | -1.55 | 0.00 | 1.25 | 0.00 | -- | -- | 0.00 | -34.75 | -47.51 | -44.42 | -59.79 | -- | -- | -- | -188.81 | -- | -- | 0.00 | -- | -- | -- | 55.53 | -- | -60.02 | -- |
| Cell Source Inc | 0.00 | -6.57m | 36.03m | -- | -- | -- | -- | -- | -0.1613 | -0.1613 | 0.00 | -0.4379 | 0.00 | -- | -- | -- | -2,039.39 | -1,758.85 | -- | -- | -- | -- | -- | -- | -- | -3.74 | -- | -- | -- | -- | -3.55 | -- | -- | -- |
| Galecto Inc | 0.00 | -15.84m | 36.10m | 5.00 | -- | 4.51 | -- | -- | -12.01 | -12.01 | 0.00 | 6.03 | 0.00 | -- | -- | 0.00 | -92.89 | -47.05 | -109.09 | -50.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 44.10 | -- | -- | -- |
| PDS Biotechnology Corp | 0.00 | -34.88m | 36.15m | 24.00 | -- | 3.48 | -- | -- | -0.8194 | -0.8194 | 0.00 | 0.1982 | 0.00 | -- | -- | 0.00 | -80.05 | -57.93 | -125.74 | -68.38 | -- | -- | -- | -- | -- | -8.43 | 0.6552 | -- | -- | -- | 12.42 | -- | -- | -- |
| Actinium Pharmaceuticals Inc | 90.00k | -34.60m | 36.19m | 37.00 | -- | 2.63 | -- | 402.08 | -1.11 | -1.11 | 0.0029 | 0.4419 | 0.0013 | -- | -- | 2,432.43 | -50.05 | -43.20 | -55.95 | -47.84 | -- | -- | -38,443.33 | -7,408.74 | -- | -- | 0.0009 | -- | -100.00 | -- | 21.66 | -- | -29.66 | -- |
| INmune Bio Inc | 50.00k | -49.89m | 37.75m | 22.00 | -- | 1.49 | -- | 755.02 | -2.14 | -2.14 | 0.0021 | 0.9546 | 0.0012 | -- | 0.0258 | 2,272.73 | -115.83 | -45.54 | -153.59 | -52.16 | -- | -- | -99,774.00 | -19,298.45 | -- | -942.22 | 0.00 | -- | -90.97 | -- | -40.24 | -- | -- | -- |
| Generation Bio Inc | 15.27m | -62.63m | 38.68m | 115.00 | -- | 0.7647 | -- | 2.53 | -9.35 | -9.35 | 2.28 | 7.51 | 0.0824 | -- | 11.73 | 132,782.60 | -33.79 | -35.85 | -39.21 | -38.42 | -- | -- | -410.13 | -2,304.98 | -- | -- | 0.00 | -- | 236.92 | -- | -3.99 | -- | -34.55 | -- |
Data as of Feb 06 2026. Currency figures normalised to Actinium Pharmaceuticals Inc's reporting currency: US Dollar USD
15.28%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.25m | 4.01% |
| District 2 Capital LPas of 08 Nov 2024 | 769.45k | 2.47% |
| Millennium Management LLCas of 30 Sep 2025 | 624.70k | 2.00% |
| Acadian Asset Management LLCas of 30 Sep 2025 | 489.58k | 1.57% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 357.64k | 1.15% |
| Geode Capital Management LLCas of 30 Sep 2025 | 328.42k | 1.05% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 288.63k | 0.93% |
| Two Sigma Investments LPas of 30 Sep 2025 | 234.29k | 0.75% |
| Gagnon Securities LLCas of 30 Sep 2025 | 226.26k | 0.73% |
| Two Sigma Advisers LPas of 30 Sep 2025 | 196.38k | 0.63% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
